Clinical Trial Update: Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating subcutaneous omalizumab for chronic rhinosinusitis with nasal polyps has completed and results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhinosinusitis with Nasal Polyps

Drugs mentioned

• Xolair (omalizumab) (omalizumab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Chronic Rhinosinusitis, Nasal Polyps | Phase 2 | Status: COMPLETED | Results posted: 2017-05-19